Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,101
  • Shares Outstanding, K 5,430
  • Annual Sales, $ 580 K
  • Annual Income, $ -14,290 K
  • 60-Month Beta 1.06
  • Price/Sales 38.10
  • Price/Cash Flow N/A
  • Price/Book 0.77
Trade APRE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.63
  • Number of Estimates 2
  • High Estimate -0.58
  • Low Estimate -0.69
  • Prior Year -0.87
  • Growth Rate Est. (year over year) +27.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.85 +5.71%
on 06/20/24
5.00 -18.60%
on 06/04/24
-1.12 (-21.58%)
since 05/28/24
3-Month
3.85 +5.71%
on 06/20/24
6.70 -39.25%
on 04/03/24
-2.62 (-39.16%)
since 03/28/24
52-Week
2.78 +46.40%
on 07/07/23
8.85 -53.99%
on 03/01/24
+1.06 (+35.22%)
since 06/28/23

Most Recent Stories

More News
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

PHAR : 8.26 (-1.08%)
KA : 0.5307 (-6.89%)
APRE : 4.07 (-0.49%)
XFOR : 0.6096 (+5.10%)
Biotech Bid Up Following First Patient Dosage

A Boston-based %Biotech company is turning heads on Wednesday after the company announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead...

APRE : 4.07 (-0.49%)
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 4.07 (-0.49%)
First Week of May 20th Options Trading For Aprea Therapeutics (APRE)

Investors in Aprea Therapeutics Inc saw new options begin trading this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the APRE options chain...

APRE : 4.07 (-0.49%)
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 4.07 (-0.49%)
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting

60% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplantMedian overall survival of 20.6 months BOSTON, Dec. ...

APRE : 4.07 (-0.49%)
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 4.07 (-0.49%)
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 4.07 (-0.49%)
Pre-Market Brief: U.S. Stocks to Open Higher on Strong U.S. Housing Data

Morning Markets Dec S&P 500 futures this morning are up by +0.62%. U.S. stock index futures are climbing today as the markets partially recover from Monday’s plunge on some dip-buying. Also, a rally...

JD : 26.17 (+1.28%)
PDD : 132.46 (-0.37%)
BABA : 72.91 (+1.26%)
NTES : 95.59 (+0.01%)
BIDU : 87.14 (+0.76%)
COP : 114.64 (+0.23%)
SRAD : 11.18 (+0.63%)
OXY : 63.10 (+0.11%)
LEN : 149.87 (unch)
APRE : 4.07 (-0.49%)
OEG : 0.6431 (+8.08%)
KAR : 16.59 (+0.48%)
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021

BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...

APRE : 4.07 (-0.49%)

Business Summary

Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development...

See More

Key Turning Points

3rd Resistance Point 4.39
2nd Resistance Point 4.30
1st Resistance Point 4.19
Last Price 4.07
1st Support Level 3.99
2nd Support Level 3.90
3rd Support Level 3.79

See More

52-Week High 8.85
Fibonacci 61.8% 6.53
Fibonacci 50% 5.81
Fibonacci 38.2% 5.10
Last Price 4.07
52-Week Low 2.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar